Drugs / Pegylated rhG-CSF
Pegylated rhG-CSF
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02119715 | Feb 2011 → Aug 2012 | breast cancer, neutropenia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01560195 | Apr 2012 → Jan 2013 | neutropenia, non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01611051 | Mar 2012 → Jan 2013 | breast cancer, neutropenia | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated rhG-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02119715 ↗ |
| Known as | Pegylated Recombinant Human Granulocyte Colony Stimulating Factor | “Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)” NCT01560195 ↗ |
| Modality | Protein / enzyme biologic | “Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)” NCT01560195 ↗ |